Abattis Bioceuticals Receivables

Abattis Bioceuticals (ATTBF) currently reports a receivables of $160K as of September 2019. That compares with $570K in the prior-year period — down 72.7% year over year. Use the charts on this page to explore Abattis Bioceuticals's receivables history and peer comparisons.

Abattis Bioceuticals's receivables decreased from $570K to $160K — a 72.7% year-over-year decrease (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Abattis Bioceuticals reported $160K in receivables as of September 2019. That compares with $570K in the prior-year period — down 72.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $160K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Abattis Bioceuticals, and consider following ATTBF for alerts when major investors trade the stock.

Abattis Bioceuticals is classified in the Healthcare sector. On receivables, it currently shows $160K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATTBF with unrelated industries.